BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (NASDAQ: BIOS) is a blank-check company that completed its initial public offering in 2021 with a focus on the healthcare and life sciences sector, including biotechnology and medical technology targets. The company filed an 8-K current report with the Securities and Exchange Commission on May 3, 2023, under accession number 0001193125-23-133439, reflecting a material corporate event disclosure during its post-IPO lifecycle. BIOS was organized to identify and execute a business combination with a company operating in the broader healthcare industry. For complete filing history, sponsor details, deal timelines, and real-time status updates on BIOS and hundreds of other SPACs, sign up for full data access at SpacDesk.